State Street Corp Ovid Therapeutics Inc. Transaction History

State Street Corp

$2.21 Trillion
Q1 2024

A detailed history of State Street Corp transactions in Ovid Therapeutics Inc. stock. As of the latest transaction made, State Street Corp holds 1,155,647 shares of OVID stock, worth $889,848. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,155,647

Previous 1,120,347 3.15%

Holding current value

$889,848

Previous $3.61 Million 2.3%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.72 - $4.04 $96,016 - $142,612	35,300 Added 3.15%	1,155,647 $3.52 Million
Q4 2023 Feb 14, 2024	BUY	$2.98 - $3.78 $33,638 - $42,668	11,288 Added 1.02%	1,120,347 $3.61 Million
Q3 2023 Nov 14, 2023	BUY	$3.23 - $3.97 $266,242 - $327,239	82,428 Added 8.03%	1,109,059 $4.26 Million
Q2 2023 Aug 14, 2023	BUY	$2.53 - $3.89 $2.11 Million - $3.25 Million	834,898 Added 435.45%	1,026,631 $3.37 Million
Q1 2022 May 16, 2022	BUY	$2.65 - $3.49 $124,242 - $163,625	46,884 Added 32.37%	191,733 $602,000

Q3 2021 Nov 15, 2021	SELL	$3.31 - $4.04 $39,720 - $48,480	-12,000 Reduced 7.65%	144,849 $487,000
Q2 2021 Aug 16, 2021	SELL	$3.3 - $4.49 $3.46 Million - $4.7 Million	-1,047,516 Reduced 86.98%	156,849 $613,000
Q1 2021 May 17, 2021	BUY	$2.42 - $4.47 $1.13 Million - $2.08 Million	464,925 Added 62.88%	1,204,365 $4.84 Million
Q4 2020 Feb 16, 2021	BUY	$2.28 - $6.84 $27,834 - $83,502	12,208 Added 1.68%	739,440 $1.71 Million
Q3 2020 Nov 10, 2020	SELL	$5.39 - $8.24 $47,022 - $71,885	-8,724 Reduced 1.19%	727,232 $4.17 Million
Q2 2020 Aug 14, 2020	BUY	$2.67 - $7.91 $1.97 Million - $5.82 Million	735,956 New	735,956 $5.42 Million

Others Institutions Holding OVID

# of Institutions

Shares Held

43.2M

Call Options Held

5.9K

Put Options Held

300

View Full List

About Ovid Therapeutics Inc.

Ticker OVID
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,419,400
Market Cap $54.2M
Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...

More about OVID

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Ovid Therapeutics Inc. Transaction History